Objective To determine all cause mortality and deaths from cardiovascular events related to
intensive glucose lowering treatment in people with type 2 diabetes. Design Meta-analysis …

Background: Given the increase in medications for type 2 diabetes mellitus, clinicians and
patients need information about their effectiveness and safety to make informed choices …

(ACCF) guidelines on secondary prevention, 1 important evidence from clinical trials has
emerged that further supports and broadens the merits of intensive risk-reduction therapies …

Aims The impact of insulin secretagogues (ISs) on long-term major clinical outcomes in type
2 diabetes remains unclear. We examined mortality and cardiovascular risk associated with …

Aim: Some studies suggested that metformin could reduce cardiovascular risk to a greater
extent than that determined by glucose reduction. Aim of the present meta‐analysis is to …

Non-alcoholic fatty liver disease (NAFLD) refers to the accumulation of hepatic steatosis not
due to excess alcohol consumption. The prevalence of NAFLD is up to 30% in developed …

Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) frequently
coexist as they share the pathogenic abnormalities of excess adiposity and insulin …

Background Recent meta-analyses of randomized clinical trials (RCTs) demonstrated a
higher risk of heart failure (HF) with the use of thiazolidinediones (TZDs). However, this …

There is a rising worldwide prevalence of diabetes, especially type 2 diabetes mellitus (T 2
DM), which is one of the most challenging health problems in the 21st century. The …

Recent highly publicized withdrawals of drugs from the market because of safety concerns
raise the question of whether these events are random failures or part of a recurring pattern …